Results 31 to 40 of about 188,791 (289)

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial [PDF]

, 2019
Aprospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (RHDS) versus conventional chemotherapy with rituximab (CHOP-R) as firstline therapy in 134 high-risk follicular ...
Angrilli, F., Barbui, A. M., Benedetti, F., Billio, A., Boccomini, C., Bruna, R., Castellino, C., Ciceri, F., Corradini, P., Devizzi, L., Di Raimondo, F., Dondi, A., Gini, G., Gueli, A., Ladetto, M., Lanza, F., Liberati, A. M., Mantoan, B., Massimo Gianni, A., Musso, M., Narni, F., Parvis, G., Passera, R., Patti, C., Perrone, T., Pulsoni, A., Rambaldi, A., Rossini, F., Rota-Scalabrini, D., Semenzato, G., Stelitano, C., Tarella, C., Tucci, A., Zallio, F., Zoli, V.   +34 more
core   +4 more sources

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Haematologica, 2013
Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high ...
Clifton C. Mo, Ndegwa Njuguna, Paul V. Beum, Margaret A. Lindorfer, Berengere Vire, Elinor Lee, Gerald Marti, Wyndham H Wilson, Ronald P. Taylor, Adrian Wiestner   +9 more
doaj   +1 more source

Noninvasive Urinary Monitoring of Progression in IgA Nephropathy. [PDF]

, 2019
Standard methods for detecting and monitoring of IgA nephropathy (IgAN) have conventionally required kidney biopsies or suffer from poor sensitivity and specificity.
Fervenza, Fernando C, Lafayette, Richard A, Sarwal, Minnie M, Sarwal, Reuben D, Yang, Joshua YC   +4 more
core   +1 more source

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

Journal of Hematology & Oncology, 2012
Background The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituximab versus rituximab.
Zinzani Pier, Khuageva Nuriet K, Wang Huaqing, Garicochea Bernardo, Walewski Jan, Van Hoof Achiel, Soubeyran Pierre, Caballero Dolores, Buckstein Rena, Esseltine Dixie-Lee, Theocharous Panteli, Enny Christopher, Zhu Eugene, Elsayed Yusri A, Coiffier Bertrand   +14 more
doaj   +1 more source

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. [PDF]

, 2014
BackgroundCurrent treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy.
Beca, Jaclyn, Bell, Chaim M, Bremner, Karen E, Crump, Michael, Gavura, Scott, Hoch, Jeffrey S, Hodgson, David, Khor, Sara, Krahn, Murray, Lee, Linda, Luo, Jin, Mamdani, Muhammad, Peacock, Stuart, Sawka, Carol, Sullivan, Terrence, Trudeau, Maureen   +15 more
core   +2 more sources

Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. [PDF]

, 2014
BackgroundIndividuals with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease, partly due to systemic inflammation and endothelial dysfunction.
Del Puerto, Gus, Ganz, Peter, Graf, Jonathan, Grunfeld, Carl, Hsue, Priscilla Y, Imboden, John, Nitta, Elaine, Scherzer, Rebecca, Schnell Heringer, Amanda, Shigenaga, Judy, Wu, Yuaner   +10 more
core   +2 more sources

Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E [PDF]

, 2020
Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is usually characterized by a self-limited course. However, there is an increased risk of HEV persistence in immunocompromised risk populations, comprising ...
Biedermann, Paula, Bock, Claus-Thomas, Choi, Mira, Hanitsch, Leif Gunnar, Hofmann, Jörg, Mueller, Tobias, Schulz, Marten, Tacke, Frank   +7 more
core   +1 more source

Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study

BMC Rheumatology, 2022
Background This pilot study’s primary aim was to determine if oligoclonal B cell expansion in children with Juvenile Dermatomyositis (JDM) predicts response to Rituximab therapy.
Elisa Ochfeld, Victoria Hans, Wil Marin, Najah Ahsan, Gabrielle Morgan, Lauren M. Pachman, Amer Khojah   +6 more
doaj   +1 more source

Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages [PDF]

, 2015
We have read with great interest the recent article of Kohrt, H.E. et al1 showing that Ibrutinib prevented NK cell mediated cytotoxicity of antibody-coated CLL cells in vitro.
Almejún, María Belén, Bezares, Raimundo F., Borge, Mercedes, Cabrejo, María, Colado, Ana, Fernández Grecco, Horacio, Gamberale, Romina, Giordano, Mirta Nilda, Podaza, Enrique Arturo   +8 more
core   +2 more sources

Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. [PDF]

PLoS ONE, 2013
The CD20-specific monoclonal antibody rituximab (MabThera(®), Rituxan(®)) is widely used as the backbone of treatment for patients with hematologic disorders. Intravenous administration of rituximab is associated with infusion times of 4-6 hours, and can
Cheng-Ping Mao, Martin R Brovarney, Karim Dabbagh, Herbert F Birnböck, Wolfgang F Richter, Christopher J Del Nagro   +5 more
doaj   +1 more source